|
Atomistry » Fluorine » PDB 4b00-4bjk » 4b05 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Atomistry » Fluorine » PDB 4b00-4bjk » 4b05 » |
Fluorine in PDB 4b05: Preclinical Characterization of AZD3839, A Novel Clinical Candidate BACE1 Inhibitor For the Treatment of Alzheimer DiseaseEnzymatic activity of Preclinical Characterization of AZD3839, A Novel Clinical Candidate BACE1 Inhibitor For the Treatment of Alzheimer Disease
All present enzymatic activity of Preclinical Characterization of AZD3839, A Novel Clinical Candidate BACE1 Inhibitor For the Treatment of Alzheimer Disease:
3.4.23.46; Protein crystallography data
The structure of Preclinical Characterization of AZD3839, A Novel Clinical Candidate BACE1 Inhibitor For the Treatment of Alzheimer Disease, PDB code: 4b05
was solved by
F.Jeppsson,
S.Eketjall,
J.Janson,
S.Karlstrom,
S.Gustavsson,
L.L.Olsson,
A.C.Radesater,
B.Ploeger,
G.Cebers,
K.Kolmodin,
B.M.Swahn,
S.Von Berg,
T.Bueters,
J.Falting,
with X-Ray Crystallography technique. A brief refinement statistics is given in the table below:
Other elements in 4b05:
The structure of Preclinical Characterization of AZD3839, A Novel Clinical Candidate BACE1 Inhibitor For the Treatment of Alzheimer Disease also contains other interesting chemical elements:
Fluorine Binding Sites:
The binding sites of Fluorine atom in the Preclinical Characterization of AZD3839, A Novel Clinical Candidate BACE1 Inhibitor For the Treatment of Alzheimer Disease
(pdb code 4b05). This binding sites where shown within
5.0 Angstroms radius around Fluorine atom.
In total 3 binding sites of Fluorine where determined in the Preclinical Characterization of AZD3839, A Novel Clinical Candidate BACE1 Inhibitor For the Treatment of Alzheimer Disease, PDB code: 4b05: Jump to Fluorine binding site number: 1; 2; 3; Fluorine binding site 1 out of 3 in 4b05Go back to Fluorine Binding Sites List in 4b05
Fluorine binding site 1 out
of 3 in the Preclinical Characterization of AZD3839, A Novel Clinical Candidate BACE1 Inhibitor For the Treatment of Alzheimer Disease
Mono view Stereo pair view
Fluorine binding site 2 out of 3 in 4b05Go back to Fluorine Binding Sites List in 4b05
Fluorine binding site 2 out
of 3 in the Preclinical Characterization of AZD3839, A Novel Clinical Candidate BACE1 Inhibitor For the Treatment of Alzheimer Disease
Mono view Stereo pair view
Fluorine binding site 3 out of 3 in 4b05Go back to Fluorine Binding Sites List in 4b05
Fluorine binding site 3 out
of 3 in the Preclinical Characterization of AZD3839, A Novel Clinical Candidate BACE1 Inhibitor For the Treatment of Alzheimer Disease
Mono view Stereo pair view
Reference:
F.Jeppsson,
S.Eketjall,
J.Janson,
S.Karlstrom,
S.Gustavsson,
L.L.Olsson,
A.C.Radesater,
B.Ploeger,
G.Cebers,
K.Kolmodin,
B.M.Swahn,
S.Von Berg,
T.Bueters,
J.Falting.
Discovery of AZD3839, A Potent and Selective BACE1 Inhibitor Clinical Candidate For the Treatment of Alzheimer Disease. J. Biol. Chem. V. 287 41245 2012.
Page generated: Thu Aug 1 00:06:39 2024
ISSN: ESSN 1083-351X PubMed: 23048024 DOI: 10.1074/JBC.M112.409110 |
Last articlesZn in 9JPJZn in 9JP7 Zn in 9JPK Zn in 9JPL Zn in 9GN6 Zn in 9GN7 Zn in 9GKU Zn in 9GKW Zn in 9GKX Zn in 9GL0 |
© Copyright 2008-2020 by atomistry.com | ||
Home | Site Map | Copyright | Contact us | Privacy |